Annals of Surgical Oncology, Vol 4, Issue 1 19-23, Copyright © 1997 by Society of Surgical Oncology

ARTICLES

Multiple primary melanomas: implications for screening and follow-up programs for melanoma

A. Brobeil, D. Rapaport, K. Wells, C. W. Cruse, F. Glass, N. Fenske, J. Albertini, G. Miliotis, J. Messina, R. DeConti, C. Berman, A. Shons, A. Cantor and D. S. Reintgen
Cutaneous Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa 33612-9497, USA.

BACKGROUND: Once individuals are diagnosed with malignant melanoma, they are at an increased risk of developing another melanoma when compared with the normal population. METHODS: To determine the impact of an intensive follow-up protocol on the stage of disease at diagnosis of subsequent primary melanomas, a retrospective query was performed of an electronic medical record database of 2,600 consecutively registered melanoma patients. RESULTS: Sixty-seven patients (2.6%) had another melanoma diagnosed at the time of presentation to the clinic or within 2 months (synchronous) and another 44 patients (1.7%) developed a second primary melanoma during the follow-up period (metachronous). For the 44 patients diagnosed with metachronous lesions, the Breslow mean tumor thickness for the first invasive melanoma was 2.27 mm compared with 0.90 mm for the second melanoma. The first melanomas diagnosed are thicker by an average of 3.8 mm (p = 0.008). The mean Clark level for the initial melanoma was greater than the mean level for subsequently diagnosed melanomas (p = 0.002). Twenty-three percent of the initial melanomas were ulcerated, whereas only one of the second primary lesions showed this adverse prognostic factor (p = 0.002). CONCLUSIONS: Once individuals are diagnosed with melanoma, they are in a high-risk population for having other primary site melanomas diagnosed and should be placed in an intensive follow-up protocol consisting of a complete skin examination.

This article has been cited by other articles:

				K. M. Dalal, Q. Zhou, K. S. Panageas, M. S. Brady, D. P. Jaques, and D. G. Coit Methods of Detection of First Recurrence in Patients with Stage I/II Primary Cutaneous Melanoma After Sentinel Lymph Node Biopsy Ann. Surg. Oncol., August 1, 2008; 15(8): 2206 - 2214. [Abstract] [Full Text] [PDF]

				A. B. Francken, H. M. Shaw, N. A. Accortt, S.-J. Soong, H. J. Hoekstra, and J. F. Thompson Detection of First Relapse in Cutaneous Melanoma Patients: Implications for the Formulation of Evidence-Based Follow-up Guidelines Ann. Surg. Oncol., June 1, 2007; 14(6): 1924 - 1933. [Abstract] [Full Text] [PDF]

				C. R. Ferrone, L. Ben Porat, K. S. Panageas, M. Berwick, A. C. Halpern, A. Patel, and D. G. Coit Clinicopathological Features of and Risk Factors for Multiple Primary Melanomas JAMA, October 5, 2005; 294(13): 1647 - 1654. [Abstract] [Full Text] [PDF]

				A. Doubrovsky and S. W. Menzies Enhanced Survival in Patients With Multiple Primary Melanoma Arch Dermatol, August 1, 2003; 139(8): 1013 - 1018. [Abstract] [Full Text] [PDF]

				J. Hashemi, A. Platz, T. Ueno, U. Stierner, U. Ringborg, and J. Hansson CDKN2A Germ-line Mutations in Individuals with Multiple Cutaneous Melanomas Cancer Res., December 1, 2000; 60(24): 6864 - 6867. [Abstract] [Full Text]

				A. Borg, T. Sandberg, K. Nilsson, O. Johannsson, M. Klinker, A. Masback, J. Westerdahl, H. Olsson, and C. Ingvar High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families J Natl Cancer Inst, August 2, 2000; 92(15): 1260 - 1266. [Abstract] [Full Text] [PDF]

				J. Monzon, L. Liu, H. Brill, A. M. Goldstein, M. A. Tucker, L. From, J. McLaughlin, D. Hogg, and N. J. Lassam CDKN2A Mutations in Multiple Primary Melanomas N. Engl. J. Med., March 26, 1998; 338(13): 879 - 887. [Abstract] [Full Text] [PDF]